Vectura Group PLC (VEC) Receives GBX 174.86 Average Price Target from Analysts

Shares of Vectura Group PLC (LON:VEC) have been given an average recommendation of “Buy” by the ten brokerages that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is GBX 169.14 ($2.34).

Several brokerages have recently weighed in on VEC. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Vectura Group in a research report on Monday, January 15th. Shore Capital reissued a “buy” rating on shares of Vectura Group in a research report on Thursday, January 4th. Peel Hunt reissued a “hold” rating and set a GBX 160 ($2.21) price target on shares of Vectura Group in a research report on Thursday, January 4th. Numis Securities reissued a “buy” rating and set a GBX 170 ($2.35) price target on shares of Vectura Group in a research report on Thursday, January 4th. Finally, Royal Bank of Canada raised shares of Vectura Group to a “sector performer” rating and set a GBX 119 ($1.64) price target on the stock in a research report on Thursday, December 14th.

Vectura Group (LON:VEC) opened at GBX 80 ($1.11) on Tuesday. Vectura Group has a 1 year low of GBX 70.50 ($0.97) and a 1 year high of GBX 166.97 ($2.31).

ILLEGAL ACTIVITY NOTICE: This report was first published by BBNS and is the property of of BBNS. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://baseballnewssource.com/markets/vectura-group-plc-vec-receives-gbx-174-86-average-price-target-from-analysts/1886530.html.

Vectura Group Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.